The November 19, 2026 pre-submission conference with the FDA is the next binary catalyst. Watch for any updates on study design alignment or manufacturing readiness that could de-risk the conditional approval timeline. The 2027 launch target is aspirational and contingent on regulatory and manufacturing milestones.
Price Chart
Executive Summary
Endovia Health Sciences announced that the FDA's Center for Veterinary Medicine determined CannEpil qualifies as a 'minor use' for canine bone cancer pain under the MUMS program, establishing eligibility for a conditional approval pathway. A pre-submission conference with the FDA is scheduled for November 19, 2026, and the company is working toward a potential 2027 veterinary launch. This is a regulatory milestone for a pre-revenue cannabinoid biotech, but no financial data or approval certainty is provided.
Key Facts
- FDA determined CannEpil qualifies as a 'minor use' for canine bone cancer pain under the MUMS program
- CannEpil is now eligible to pursue the FDA's conditional approval pathway for a New Animal Drug Application (NADA)
- Pre-Submission Conference with FDA's Center for Veterinary Medicine scheduled for November 19, 2026
- Endovia and Lupvindol are actively sourcing U.S.-based manufacturing capabilities to support a potential 2027 commercial launch
- CannEpil remains an investigational new animal drug and has not been approved or conditionally approved by the FDA
Financial Impact
No financial figures disclosed; pre-revenue company with no reported revenue, EPS, or deal values in the filing.
Risk Factors
- CannEpil has not been approved or conditionally approved by the FDA; regulatory pathway remains uncertain
- Company is pre-revenue and may require additional financing to fund development and manufacturing
- Potential 2027 launch is subject to successful completion of FDA requirements, manufacturing readiness, and other factors
- Minor use designation limits addressable market size for the veterinary indication
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-001312 |
| Document: e7991_ex99-1.htm | 0001731122-26-001312 |
| Document: 0001731122-26-001312-index-headers.html | 0001731122-26-001312 |
| Document: 0001731122-26-001312-index.html | 0001731122-26-001312 |
| Document: 0001731122-26-001312.txt | 0001731122-26-001312 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | SC 13G | $0.1600 $0.1577 | ▼ −1.44% | ▼ −2.15% | $0.1577 (−1.44%) |
Oct 15, 2026 11d ago | 8-K | $0.1460 $0.1350 | ▲ +7.53% | ▲ +7.96% | $0.1577 (−8.01%) |
Oct 6, 2026 20d ago | 8-K | $0.1650 $0.1599 | ▲ +3.09% | ▲ +2.67% | $0.1577 (+4.42%) |
Oct 5, 2026 21d ago | DEF 14A | $0.1679 $0.1650 | ▲ +1.73% | ▲ +1.49% | $0.1577 (+6.08%) |
Oct 5, 2026 21d ago | 8-K | $0.1680 $0.1650 | ▼ −1.79% | ▼ −1.55% | $0.1577 (−6.13%) |
Aug 31, 2026 8w ago | 8-K | $0.2954 $0.2614 | ▼ −11.51% | ▼ −11.95% | $0.1577 (−46.61%) |
Aug 25, 2026 8w ago | EFFECT | $0.4182 $0.3650 | ▲ +12.72% | ▲ +12.74% | $0.1577 (+62.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers